1 |
Decreased viability |
GR00173-A |
11.02 |
AURKB |
2 |
Decreased viability |
GR00221-A-1 |
11.02 |
AXL IGF1R AURKB PIK3CB SMARCB1 |
3 |
Decreased viability |
GR00221-A-2 |
11.02 |
AXL IGF1R AURKB CHEK2 SMARCB1 |
4 |
Decreased viability |
GR00221-A-3 |
11.02 |
IGF1R CHEK2 PIK3CB SMARCB1 JAK3 |
5 |
Decreased viability |
GR00221-A-4 |
11.02 |
AXL AURKB CHEK2 PIK3CB |
6 |
Decreased viability |
GR00249-S |
11.02 |
AURKB SMARCB1 |
7 |
Decreased viability |
GR00301-A |
11.02 |
AXL ERBB4 IGF1R |
8 |
Decreased viability |
GR00342-S-1 |
11.02 |
ERBB4 |
9 |
Decreased viability |
GR00342-S-2 |
11.02 |
IGF1R CHEK2 |
10 |
Decreased viability |
GR00381-A-1 |
11.02 |
PIK3CB SMARCB1 |
11 |
Decreased viability |
GR00402-S-2 |
11.02 |
IGF1R PIK3CB JAK3 |
12 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-1 |
10.4 |
CHEK2 |
13 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-10 |
10.4 |
AURKB |
14 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-11 |
10.4 |
JAK3 |
15 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-112 |
10.4 |
CHEK2 |
16 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-114 |
10.4 |
CHEK2 |
17 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-120 |
10.4 |
CHEK2 |
18 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-123 |
10.4 |
CHEK2 |
19 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-131 |
10.4 |
AURKB |
20 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-134 |
10.4 |
PIK3CB |
21 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-142 |
10.4 |
CHEK2 |
22 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-149 |
10.4 |
JAK3 |
23 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-153 |
10.4 |
IGF1R |
24 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-163 |
10.4 |
AURKB |
25 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-176 |
10.4 |
SMARCB1 |
26 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-194 |
10.4 |
SMARCB1 |
27 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-196 |
10.4 |
AURKB |
28 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-20 |
10.4 |
JAK3 |
29 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-21 |
10.4 |
AURKB |
30 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-22 |
10.4 |
PIK3CB |
31 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-60 |
10.4 |
CHEK2 IGF1R JAK3 PIK3CB |
32 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-68 |
10.4 |
AURKB |
33 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-73 |
10.4 |
AXL |
34 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-75 |
10.4 |
SMARCB1 |
35 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-85 |
10.4 |
CHEK2 IGF1R JAK3 PIK3CB AURKB AXL |
36 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-95 |
10.4 |
AURKB |
37 |
Increased shRNA abundance (Z-score > 2) |
GR00366-A-96 |
10.4 |
JAK3 |
38 |
Decreased substrate adherent cell growth |
GR00193-A-1 |
9.91 |
AXL IGF1R |
39 |
Decreased substrate adherent cell growth |
GR00193-A-2 |
9.91 |
AURKB |
40 |
Decreased substrate adherent cell growth |
GR00193-A-3 |
9.91 |
AXL CHEK2 |
41 |
Decreased substrate adherent cell growth |
GR00193-A-4 |
9.91 |
AURKB AXL CHEK2 IGF1R |
42 |
Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) |
GR00104-A-0 |
9.67 |
AURKB AXL CUL3 PIK3CB |
43 |
Increased cell viability after pRB stimulation |
GR00230-A-1 |
9.33 |
CHEK2 ERBB4 IGF1R |
44 |
Increased Nanog expression |
GR00371-A-1 |
9.32 |
CIC SETD5 |
45 |
Increased Nanog expression |
GR00371-A-2 |
9.32 |
CIC SETD5 |
46 |
Increased Nanog expression |
GR00371-A-3 |
9.32 |
AURKB CIC SETD5 |
47 |
Increased Nanog expression |
GR00371-A-4 |
9.32 |
SETD5 |
48 |
Increased Nanog expression |
GR00371-A-5 |
9.32 |
CIC SETD5 |